AIM ImmunoTech Inc
AIM1.440USD
+0.079+5.83%
收盘 12/19, 16:00（美东）报价延迟15分钟
3.98M总市值
亏损市盈率 TTM
关于 AIM ImmunoTech Inc 公司
AIM ImmunoTech Inc. is an immuno-pharma company. The Company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) and highly selective TLR3 agonist immuno-modulator, which is being developed for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe chronic fatigue syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM ImmunoTech Inc简介
公司代码AIM
公司名称AIM ImmunoTech Inc
上市日期Jul 12, 1996
CEOEquels (Thomas K)
员工数量21
证券类型Ordinary Share
年结日Jul 12
公司地址2117 Sw Highway 484
城市OCALA
上市交易所NASDAQ OMX – NASDAQ Basic Amex
国家United States of America
邮编32801
电话13524487797
网址https://aimimmuno.com/
公司代码AIM
上市日期Jul 12, 1996
CEOEquels (Thomas K)
AIM ImmunoTech Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.87K
-0.04%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-0.08%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
641.00
-0.16%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Jenene Thomas
Ms. Jenene Thomas
Investor Relations
Investor Relations
--
--
Mr. Peter W. Rodino, III
Mr. Peter W. Rodino, III
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
Chief Operating Officer, Executive Director - Governmental Relations, General Counsel, Company Secretary
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Thomas K. Equels, Esq., J.D.
Mr. Thomas K. Equels, Esq., J.D.
President, Chief Executive Officer, Executive Vice Chairman of the Board
President, Chief Executive Officer, Executive Vice Chairman of the Board
38.87K
-0.04%
Mr. Ted D. Kellner
Mr. Ted D. Kellner
Independent Director
Independent Director
19.70K
+196850.00%
Dr. William M. Mitchell, M.D., Ph.D.
Dr. William M. Mitchell, M.D., Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
5.22K
-0.08%
Ms. Nancy K. Bryan
Ms. Nancy K. Bryan
Independent Director
Independent Director
2.92K
-0.03%
Mr. David I. Chemerow
Mr. David I. Chemerow
Independent Director
Independent Director
641.00
-0.16%
Mr. Robert (Rob) Dickey, IV
Mr. Robert (Rob) Dickey, IV
Chief Financial Officer
Chief Financial Officer
--
--
收入明细
由于公司未披露，未能获取相关数据
由于公司未披露，未能获取相关数据
业务
地区
由于公司未披露，未能获取相关数据
股东统计
更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
DRW Securities, LLC
1.52%
Equels (Thomas K)
1.36%
Kellner (Theodore D)
1.30%
Sabby Management, LLC
1.01%
The Vanguard Group, Inc.
0.61%
其他
94.19%
持股股东
持股股东
占比
DRW Securities, LLC
1.52%
Equels (Thomas K)
1.36%
Kellner (Theodore D)
1.30%
Sabby Management, LLC
1.01%
The Vanguard Group, Inc.
0.61%
其他
94.19%
股东类型
持股股东
占比
Individual Investor
3.85%
Investment Advisor
2.18%
Investment Advisor/Hedge Fund
1.58%
其他
92.39%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
56
107.25K
2.64%
--
2025Q3
59
107.25K
2.79%
+95.13K
2025Q2
58
12.12K
12.55%
-36.20K
2025Q1
67
48.31K
13.00%
-45.65K
2024Q4
64
46.48K
14.87%
-43.65K
2024Q3
61
90.13K
15.18%
+5.69K
2024Q2
61
84.44K
8.12%
+43.50K
2024Q1
64
40.95K
9.51%
-6.49K
2023Q4
65
41.55K
9.71%
-1.72K
2023Q3
69
43.37K
10.32%
-1.62K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Equels (Thomas K)
38.88K
1.44%
+210.00
+0.54%
Jun 13, 2025
Kellner (Theodore D)
19.70K
0.73%
+19.68K
+196850.00%
Apr 11, 2025
Deutsch (Todd A)
17.16K
0.63%
--
--
Dec 19, 2024
Mitchell (William M)
5.22K
0.19%
+1.97K
+60.53%
Apr 11, 2025
Rodino (Peter W III)
4.02K
0.15%
+5.00
+0.12%
Apr 04, 2025
Appelrouth (Stewart L.)
3.89K
0.14%
+670.00
+20.82%
Dec 31, 2024
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
Mar 03, 2025
Merger
100→1
公告日期
类型
比率
Mar 03, 2025
Merger
100→1
常见问题
AIM ImmunoTech Inc的前五大股东是谁？
AIM ImmunoTech Inc 的前五大股东如下：
Equels (Thomas K)持有股份：38.88K，占总股份比例：1.44%。
Kellner (Theodore D)持有股份：19.70K，占总股份比例：0.73%。
Deutsch (Todd A)持有股份：17.16K，占总股份比例：0.63%。
Mitchell (William M)持有股份：5.22K，占总股份比例：0.19%。
Rodino (Peter W III)持有股份：4.02K，占总股份比例：0.15%。
Equels (Thomas K)持有股份：38.88K，占总股份比例：1.44%。
Kellner (Theodore D)持有股份：19.70K，占总股份比例：0.73%。
Deutsch (Todd A)持有股份：17.16K，占总股份比例：0.63%。
Mitchell (William M)持有股份：5.22K，占总股份比例：0.19%。
Rodino (Peter W III)持有股份：4.02K，占总股份比例：0.15%。
AIM ImmunoTech Inc的前三大股东类型是什么？
AIM ImmunoTech Inc 的前三大股东类型分别是：
DRW Securities, LLC
Equels (Thomas K)
Kellner (Theodore D)
DRW Securities, LLC
Equels (Thomas K)
Kellner (Theodore D)
有多少机构持有AIM ImmunoTech Inc(AIM)的股份？
截至2025Q4，共有56家机构持有AIM ImmunoTech Inc的股份，合计持有的股份价值约为107.25K，占公司总股份的2.64%。与2025Q3相比，机构持股有所增加，增幅为-0.15%。
哪个业务部门对AIM ImmunoTech Inc的收入贡献最大？
在--，--业务部门对AIM ImmunoTech Inc的收入贡献最大，创收--，占总收入的--%。
